Investment Thesis
Clearside Biomedical faces severe financial distress with negative stockholders' equity of -$54.0M, indicating liabilities exceed assets by a significant margin. The company is burning cash rapidly with -$16.0M operating cash flow against only $6.8M in cash reserves, providing minimal runway. Revenue has collapsed 79.8% YoY while operating losses exceed -$15.8M, demonstrating a non-viable business model at current scale.
Strengths
- Current ratio of 2.98x provides short-term liquidity buffer despite negative equity
- Relatively low long-term debt of $385.0K limits additional leverage burden
- Pharmaceutical sector positioning in specialized treatments if development succeeds
Risks
- Negative stockholders' equity of -$54.0M indicates technical insolvency and high bankruptcy risk
- Cash burn rate of -$16.0M annually against $6.8M cash implies runway of less than 5 months
- Severe revenue decline of -79.8% YoY signals complete loss of commercial traction
- Negative operating margin of -523.1% and net margin of -618.3% demonstrate unsustainable unit economics
- Zero insider buying in last 90 days and no evidence of strategic confidence
Key Metrics to Watch
- Monthly cash burn rate and cash position deterioration
- Revenue stabilization or evidence of new commercial contracts
- Stockholders' equity trajectory and capital restructuring plans
- Operating cash flow improvement toward sustainability threshold
Financial Metrics
Revenue
3.0M
Net Income
-18.7M
EPS (Diluted)
$-3.61
Free Cash Flow
-16.0M
Total Assets
11.6M
Cash
6.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-523.1%
Net Margin
-618.3%
ROE
N/A
ROA
-160.6%
FCF Margin
-530.9%
Balance Sheet & Liquidity
Current Ratio
2.98x
Quick Ratio
2.98x
Debt/Equity
N/A
Debt/Assets
563.4%
Interest Coverage
N/A
Long-term Debt
385.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T12:52:10.951245 |
Data as of: 2025-09-30 |
Powered by Claude AI